China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its Category 1 drug candidate STC007 for postoperative pain. This marks a significant milestone in the development of this innovative therapy.
Drug Mechanism and Preclinical Results
STC007 is a polypeptide KOR agonist that binds to the KOR receptor, an inhibitory G protein-coupled receptor (GPCR). Upon binding, it activates the receptor-coupled G protein to inhibit adenylate cyclase, reducing the generation of cyclic adenosine monophosphate (cAMP) in postsynaptic neurons. This action inhibits the influx of Ca2+, stimulates K2+ efflux to cause hyperpolarization, reduces the release of neurotransmitters, and produces postsynaptic inhibition, effectively blocking and inhibiting the transmission of pain signals to produce an analgesic effect. Preclinical studies have shown that STC007 demonstrated a good analgesic effect in three rodent pain models. Toxicology studies revealed no obvious adverse reactions, indicating a favorable druggability and safety profile with no significant risk of addiction.
Future Outlook
The approval from the NMPA to proceed with clinical trials for STC007 underscores Sun-Novo Pharmaceutical’s commitment to advancing innovative treatments for postoperative pain. With its unique mechanism and promising preclinical results, STC007 has the potential to address significant unmet needs in pain management.-Fineline Info & Tech
